We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’ Substack by Kontra. In this ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller’s top stock picks with huge ...

Israel’s Teva Pharmaceutical Industries has announced that the final analysis of the pan-European PEARL Phase IV migraine ...

Israeli generics major Teva Pharmaceutical Industries has highlighted that Europe is experiencing increasing pressure on its ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...

Teva Pharmaceutical Industries (NYSE:TEVA), listed on the NYSE Composite, operates in the global healthcare and ...

Teva Pharmaceutical Industries Ltd. announced the final analysis of the PEARL Phase 4 study at the European Academy of Neurology Congress 2025, confirming that AJOVY ...

Teva Pharmaceuticals announced it would sell a “lower-cost” alternative to Syprine, an old drug that costs more than $21,000. But the new generic version costs nearly as much. By Katie Thomas ...

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and ...

Improving access to medicines and healthcare requires a continued effort to develop new evidence-based solutions that address ...

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...